Pharmacological agents targeting autophagy and their effects on lipolysis in human adipocytes

Mol Cell Endocrinol. 2022 Mar 15:544:111555. doi: 10.1016/j.mce.2022.111555. Epub 2022 Jan 12.

Abstract

Adipose tissue of metabolically compromised humans with obesity is often characterized by impaired regulation of autophagy pathway. However, data on the role of autophagy in human adipocyte lipid catabolism is scarce. Therefore, we investigated the effect of pharmacological agents (including 3-methyladenine (3MA), bafilomycin A1 (BAF), chloroquine (CQ) and lalistat-2 (L-stat), that target different stages of the autophagy pathway on lipid hydrolysis in differentiated human multipotent adipose-derived stem cells (hMADs). Glycerol and fatty acid release were measured as marker of lipid hydrolysis following starvation and β-adrenergic stimulation. Microtubule-associated protein light chain 3 ratio (LC3II/LC3I) and HSL phosphorylation (pHSL) were analyzed by Western blot. Our data indicate that pharmacological inhibition of the autophagy pathway reduced lipid hydrolysis in human adipocytes, although to a limited extent (10-15%). However, further research is needed to reveal the exact mechanism of action of these pharmacological agents and their interplay with cytosolic lipid breakdown in human adipocytes.

Keywords: Autophagy; Autophagy pharmacological inhibitors; Human adipocyte; Lipolysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipocytes* / metabolism
  • Adipose Tissue / metabolism
  • Autophagy
  • Humans
  • Lipolysis*
  • Microtubule-Associated Proteins / metabolism

Substances

  • Microtubule-Associated Proteins